SABCS 2019: Tucatinib: A New Standard of Care for HER2-Positive Metastatic Breast Cancer?
Dr. Murthy discusses the results of the HER2CLIMB study that she presented at the 2019 San Antonio Breast Cancer Symposium showing that the experimental medicine tucatinib offers benefits to people diagnosed with HER2-positive metastatic breast cancer and may be a new standard of care.
Listen to the episode to hear Dr. Murthy explain:
a summary of the study results
why this study included people with brain metastases
the side effects of tucatinib
why she thinks the results are practice changing
Dr. Rashmi Murthy is assistant professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston.
— Last updated on June 29, 2022, 2:49 PM
This content made possible by Lilly Oncology.